Engflag

Etizolam

Quick links to important sections

Etizolam

Etizolam_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Etizolam

What is Etizolam?

Etizolam is a psychoactive substance belonging to the thienodiazepine class. While it is chemically related to benzodiazepines, it differs structurally because the benzene ring has been replaced by a thiophene ring. This structural nuance classifies it as an analogue, though it shares many pharmacological properties with traditional benzodiazepine medications.

Chemical Classification

As a thienodiazepine, etizolam acts as a central nervous system (CNS) depressant. It functions by modulating the gamma-aminobutyric acid (GABA) receptors in the brain, specifically by increasing the efficiency of the neurotransmitter GABA. This action results in a slowing of neural activity, leading to several characteristic effects:

  • Anxiolytic: Reduction of emotional and physical tension associated with anxiety.
  • Sedative-Hypnotic: Induction of calmness or sleepiness.
  • Anticonvulsant: Suppression of excessive electrical activity in the brain.
  • Skeletal Muscle Relaxant: Reduction of muscle tone and tension.

History and Use

Etizolam was first patented in the 1970s and subsequently introduced for medical use in various international markets. In clinical settings where it is utilized, it is typically indicated for the short-term management of insomnia and various anxiety disorders, including panic disorder and generalized anxiety.

Due to its potency and its effect on the reward system of the brain, the substance is recognized for its potential for dependence. In many regions, it is not approved for medical use and may be regulated as a controlled substance or available primarily through research chemical markets. It is frequently found in different formulations, including oral tablets, pellets, or powder forms.

What side effects are possible with Etizolam?

Possible Side Effects and Safety Information

Official regulatory documents classify the possible adverse effects of Etizolam according to their frequency and the body system affected. These effects primarily concern the central nervous system, reflecting the drug's properties as a thienodiazepine derivative.

Commonly Documented Adverse Reactions

The most commonly listed adverse effects in official labeling are typically related to central nervous system depression. These include drowsiness (somnolence), sedation, dizziness, muscle weakness, and ataxia (loss of coordination or unsteadiness). These effects are generally recognized as being more noticeable at the start of treatment. Other common reported effects include confusion, headache, and amnesia (memory difficulties).

Serious Adverse Reactions and Safety Constraints

The regulatory profile formally notes the risk of serious adverse reactions, which are often rare but clinically significant. These include respiratory depression, particularly when the medicine is used with other central nervous system depressants, such as opioids. Severe dependence and a potentially life-threatening acute withdrawal syndrome (including seizures or psychosis) are documented risks associated with abrupt cessation after regular use. Rare, severe hypersensitivity reactions like angioedema (swelling of the larynx or glottis) have also been reported.

Population-Specific Safety Considerations

Safety labeling includes specific warnings for certain populations. Older adults are recognized as being at increased risk for profound adverse effects, including severe dizziness and unsteadiness, which increases the likelihood of falls. The medicine is also typically contraindicated in individuals with severe liver impairment, and caution is advised in patients with compromised kidney or respiratory function. Tolerance and physical dependence may develop with continued, long-term use.

Overdose and Emergency Response

Etizolam overdose primarily manifests as Central Nervous System (CNS) depression. Documented presentations range from milder signs like drowsiness, confusion, slurred speech, and ataxia (loss of coordination) to severe states of stupor or coma. The most critical, life-threatening outcome is respiratory depression (severely slowed or stopped breathing), which may occur more readily when Etizolam is taken alongside other CNS depressants, such as alcohol or opioids. Severe toxicity can result in hypotension, coma, and, in cases of mixed-substance toxicity, death.

Immediate medical attention is officially required for any signs of respiratory difficulties or abnormal vital signs. The mandated emergency response prioritizes stabilizing the patient's airway and circulation. Supportive care is the primary management for acute toxicity. While the antagonist Flumazenil is available, its routine use is officially cautioned against due to the risk of precipitating serious adverse events, including seizures and cardiac dysrhythmias. Continuous monitoring of respiratory and cardiac function is necessary. In pediatric patients, ataxia is often the most prominent sign of toxicity.

Therapeutic Uses of Etizolam

What Etizolam Treats: Main Uses and Benefits

Etizolam is commonly used for managing symptoms related to heightened physiological activity and tension. It is relevant for managing specific conditions, including generalized anxiety disorder, panic disorder, and insomnia, offering assistance in contexts marked by increased discomfort. It is applied in clinical settings that involve acute symptom patterns, where it provides support that helps ease the overall symptom burden.

Therapeutic Relief Domains

The medication is relevant for easing emotional symptoms like racing thoughts and excessive nervousness across two primary domains: emotional and physical. The physical benefit is applied to manage symptoms related to physical discomfort, such as muscle tension and spasms.

“It is commonly used when short-term symptomatic assistance is needed and can contribute to maintaining a sense of stability when symptoms are more noticeable.”

This therapeutic benefit is relevant when muscle tension and spasms become disruptive, as it provides supportive relief when physical discomfort is part of the symptomatic picture. Etizolam is relevant for conditions characterized by periods of heightened symptoms and may support general well-being during symptomatic phases when sleep is disrupted.

Quick Fact: Relief for Physical Tension Etizolam assists with managing symptoms related to physical discomfort, including muscle tension and spasms that may occur alongside emotional distress.

Eligibility and Restrictions for Use

Who Can and Cannot Use Etizolam?

Official regulatory prescribing information strictly defines population eligibility for Etizolam. The medicine is primarily approved for adult patients when used for labeled conditions.

Eligibility Status Affected Populations (Based on Regulatory Labels)
Contraindicated (Prohibited Use) Patients with acute narrow-angle glaucoma, myasthenia gravis, porphyria, or severe respiratory insufficiency. Use is also prohibited in patients with significant liver disease and those with known hypersensitivity to the drug.
Not Recommended/Not Established The pediatric population (use not established). Pregnant women and nursing mothers (use advised against or avoided).
Restricted/Conditional Use Older adults (requires restricted dose limits). Patients with non-severe impaired renal or hepatic function, depressive states, or a history of drug dependence (requires documented caution and monitoring).

These classifications govern who is permitted and who is explicitly excluded from treatment under official label conditions, based on absolute medical prohibitions or mandated cautions due to age or organ function.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Etizolam

Interaction Scope

Property Value
Medicinal product categories with documented interactions Central Nervous System (CNS) Depressants; CYP3A/CYP2C19 Inhibitors; CYP3A Inducers; MAO Inhibitors
Specific interacting medicines (if explicitly listed) Alcohol (Ethanol); Fluvoxamine; Itraconazole; Carbamazepine; Phenothiazines; Barbiturates
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic Interaction via Cytochrome P450 (CYP3A4 and CYP2C19) metabolism; Pharmacodynamic Interaction leading to additive effects
Timing-based interaction rules (if applicable) No mandatory, specific time-separation requirements are formally documented.
Population-specific interaction notes (if applicable) CYP2C19 Poor Metabolizers are at a higher risk of drug-drug interaction when co-administered with a strong CYP inhibitor.
Interaction-related restrictions Alcohol consumption must be avoided as it may intensify the medicine's effects, potentially causing functional deterioration.

Interaction Classifications (High-Level)

Property Value
Interaction severity classification (as defined in official documents) Potentiation/Intensification; Increased Exposure/Clearance Reduction; Decreased Exposure/Metabolism Acceleration
Regulatory basis National drug information sheets and related official pharmacokinetics data.
Interaction-context constraints (as defined in official documents) Caution is advised regarding over-the-counter medicines and dietary supplements.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with Alcohol (Ethanol) is restricted because it may intensify the medicinal effects, leading to deterioration of mental and motor function.
  • Interactions are reported with CNS Depressants, Phenothiazines, Barbiturates, and MAO Inhibitors.
  • Fluvoxamine and Itraconazole inhibit elimination by affecting CYP enzymes, leading to increased plasma concentration.
  • Carbamazepine induces metabolism via the CYP system, resulting in reduced pharmacological effects.
  • CYP2C19 Poor Metabolizers exhibit a significantly larger systemic exposure (AUC) and are at a higher risk of interaction severity, particularly with co-administered CYP inhibitors.

Connection to the overall interaction profile (4 sentences): Regulatory documents establish the drug's interaction profile based on two primary mechanisms: pharmacokinetic modification through the CYP enzyme system (notably CYP3A4 and CYP2C19) and pharmacodynamic reinforcement with other central nervous system depressants. This structure formally classifies specific medicinal products, such as Itraconazole and Carbamazepine, by their effect on systemic exposure. The profile includes the critical constraint that Alcohol must be avoided due to the risk of effect potentiation. Furthermore, the official labeling introduces a pharmacogenetic consideration, highlighting the increased interaction risk documented for CYP2C19 Poor Metabolizers.

Mechanism of Action

Etizolam functions as a thienodiazepine compound that modulates inhibitory pathways within the central nervous system (CNS).

Allosteric Modulation of GABA A Receptors

Etizolam acts as a positive allosteric modulator, binding to a specific site on the GABA A receptor complex, the principal inhibitory neurotransmitter receptor in the brain.

Augmenting Inhibitory Neurotransmission

Binding to this allosteric site facilitates the natural action of GABA (gamma-aminobutyric acid), causing an increase in the frequency of chloride ion channel opening. This augmented ion flow leads to a rapid influx of chloride ions into the postsynaptic neuron.

Modulation of Neuronal Excitability

The resulting change in ion concentration causes the neuronal membrane to become hyperpolarized, shifting the membrane potential further away from the firing threshold. This heightened inhibitory drive decreases the overall excitability of targeted neurons. The pathway modulation limits excessive electrical signaling across the CNS, resulting in a net inhibitory effect on neuronal activity in overactive systems.

Dosage and Administration Information

The administration of Etizolam follows specific parameters for strength and route. The medicine is supplied primarily as an oral tablet in strengths of 0.5 mg and 1 mg, and is administered by the oral route. The protocol for use, including dose magnitude and frequency, is determined by the specific condition being addressed.

Official Administration Regimens

Indication Context Standard Adult Daily Dosing Dosing Frequency
Generalized Symptoms (Anxiety) Typically 1.5 mg to 3 mg total per day. Divided doses (e.g., two or three times daily)
Sleep Disorder (Insomnia) 1 mg to 3 mg total per day. Single dose (taken before bedtime)

Contextual Usage Instructions

The maximum total daily dose for older adults is generally limited to 1.5 mg, regardless of the indication being treated. The dosage also typically requires adjustment in patients with impaired liver or kidney function.

Specific parameters exist for adherence to the schedule: if a dose is missed, it is typically taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose is skipped entirely. To avoid excessive intake, two doses are not taken at one time to compensate for a skipped amount. The use of the medication is generally restricted to short-term symptomatic management.

Recent Clinical Evidence

Research examining Etizolam was conducted in short-term Randomized Controlled Trials (RCTs) focusing on Adults with Generalized Anxiety Disorder (GAD) or Insomnia. These studies monitored outcomes related to symptom intensity, such as changes in standardized anxiety rating scales and metrics of sleep quality (sleep latency and duration).

Findings indicate that patterns observed were limited to the short duration of the study periods, typically spanning a few weeks. Some clinical trials explored how Etizolam was associated with changes in measured anxiety scores when compared against an inactive placebo or another study compound. The evidence level for these core indications is classified as Moderate.

Evidence for associated physical symptoms, such as muscle tension and spasms, is primarily derived from secondary analyses of anxiety RCTs and observational data. Dedicated research exploring the observation of physical symptoms as a primary objective is scarce, and the research involves heterogeneous methodologies, contributing to a lower certainty for this domain.

A key limitation is the absence of long-term data. The majority of evidence comes from studies observing responses over defined, short time intervals, meaning long-term effects are not fully established. Data for sustained observation, the durability of any observed response, or patient experience over several months are insufficient.

Furthermore, research involving specific patient subgroups remains highly limited. Data for certain groups are insufficient; there is little to no high-quality clinical evidence available for use in children or adolescents or in older adults with specific comorbidities. This lack of comprehensive research contributes to the overall low certainty for its use outside the original study cohort.

Key Studies & References

  1. [Clinical study of etizolam in patients with anxiety and insomnia].
  2. Etizolam: Use and safety profile in children and adolescent.
  3. Etizolam: Uses, Interactions, Mechanism of Action (DrugBank entry for regulatory context and general evidence base).

Frequently Asked Questions (FAQ)

Common questions about Etizolam (FAQ)

Q: How quickly do the effects of Etizolam typically begin after taking it?

Clinical information indicates that the onset of effects is generally observed within 30 minutes to 2 hours following oral use. Pharmacological data describes this as a relatively quick onset.

Q: How long does the primary anti-anxiety or sedative effect of Etizolam usually last?

The primary therapeutic effect of Etizolam is generally considered short-to-intermediate in duration. Official information states that the anti-anxiety or sedative effects typically last for about 6 to 8 hours.

Q: Does Etizolam have a long or short elimination half-life according to scientific literature?

Studies examining how the body processes the drug show that Etizolam has a relatively short elimination half-life. Reported average times for the body to clear half the medicine range from approximately 3.4 to 6.3 hours.

Q: What is the official legal status of Etizolam in different regions of the world?

The official legal status of Etizolam varies significantly across different regions. For example, the World Health Organization has recommended its placement under international drug control conventions, and it has been temporarily scheduled as a controlled substance in certain jurisdictions.

Q: Can Etizolam cause next-day grogginess, sometimes called a 'hangover' effect?

Official side effect information lists drowsiness and sedation as common occurrences when taking Etizolam. Official warnings indicate that residual sleepiness or impairment is possible the morning after use, sometimes described by users as a 'hangover' feeling.

Q: Are there known side effects that may occur with the long-term use of Etizolam?

Official safety warnings state that continued, long-term use is associated with several risks. These include the potential development of tolerance, physical and psychological dependence, and the possibility of a severe withdrawal syndrome if the medicine is abruptly stopped.

Q: Does Etizolam affect a person's ability to operate machinery or drive?

Official regulatory precautions mandate the avoidance of operating dangerous machinery or driving a car while using this medication. This official warning is based on the risk that Etizolam may cause side effects like sleepiness, reduced attention, and impaired reflex movement.

Q: Are there any known foods or drinks that should be avoided when taking Etizolam?

Official product information contains a specific constraint that the co-administration with alcohol must be avoided. This restriction is in place because alcohol may intensify the effects of the medicine, potentially leading to deterioration of mental and motor function.

Q: What is the difference between Etizolam and Diazepam (Valium) according to research?

Etizolam is chemically classified as a thienodiazepine while Diazepam is a benzodiazepine, but they are functionally similar. Pharmacological data indicates a difference in potency, stating that Etizolam is considered approximately 10 times more potent than Diazepam.

Q: Are there any official reports on Etizolam causing skin reactions or rashes?

Official drug information advises caution in patients with a known history of allergic reactions to any medicines, including those involving itching or rash. This is related to the possibility of serious hypersensitivity events, which are documented risks.

Q: Is Etizolam a prescription-only medicine in all countries where it is available?

In the jurisdictions where Etizolam is medically licensed, regulatory documentation provides specific dosing and administration instructions. The official process for use is consistent with its classification as a prescription-only product.

Q: Why do some sources describe Etizolam as a 'designer' benzodiazepine or a research chemical?

Public health and regulatory sources acknowledge that Etizolam is a synthetic compound chemically similar to benzodiazepines. It has gained attention in the New Psychoactive Substance (NPS) market, which is the context for the use of terms like 'designer' or 'research chemical' in unofficial discussions.

Q: What are the published findings regarding Etizolam and its use alongside depression treatment?

Official prescribing information advises caution regarding the use of Etizolam in patients who have a depressive state. This regulatory constraint necessitates close monitoring when the medicine is used in this context.

Q: Can Etizolam be reliably detected by standard benzodiazepine drug screening tests?

Detection of the original Etizolam parent drug can sometimes be difficult. This is due to the drug undergoing extensive metabolism in the liver, meaning testing often relies on identifying its breakdown products, or metabolites.

Q: How does Etizolam affect sleep patterns in individuals with insomnia?

The medicine is officially used for the treatment of sleep disorder. Clinical trials monitored metrics of sleep quality, such as how long it takes to fall asleep (sleep latency) and the total time spent sleeping (duration) to evaluate its effectiveness.

Q: Are there any reported issues with Etizolam affecting vision or causing involuntary eye movements?

Official side effect data includes reports of vision-related issues. These reported adverse effects consist of visual disturbances and, in some cases, involuntary eye closure.

Q: Does Etizolam carry an official warning about increasing suicidal thoughts or behavior?

Official safety warnings note that the medicine can potentially cause suicidal thoughts and inclinations. Therefore, regulatory documents state that use is constrained by the need for extreme caution in patients who have mental health conditions like depression.

Q: Is Etizolam known to cause changes in heart rate or blood pressure?

Official warnings indicate that the use of this medicine is known to cause cardiovascular changes. Specifically, safety data notes that its use, particularly at higher doses, can result in a fall in blood pressure.

Q: Does Etizolam have muscle-relaxant properties as part of its effects?

According to the official pharmacological profile, Etizolam has properties that extend beyond anxiety and sleep aid. Regulatory information confirms that the medicine has a confirmed muscle tone-relieving effect.

How should Etizolam be stored and disposed of?

Storage and Disposal of Etizolam

Storage Requirement Official Condition
Temperature Limit Store at a temperature not exceeding 30°C (86°F).
Environmental Protection Keep the medicine away from light, heat, and moisture; do not freeze.
Handling The container must be kept tightly closed to protect from moisture.
Safety Mandate The product must be kept out of the reach of children.

Disposal of Unused Medicine

Official regulatory guidance mandates that Etizolam, as a controlled substance, should ideally be disposed of using a drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed container, and then discarded in the household trash. The medicine must not be flushed down the toilet or poured into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Etizolam found in:

A-Z Index: